Incidence of Hepatocellular Carcinoma in Patient with Elevated Alpha Fetoprotein before DAAS | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 122, Volume 85, Issue 1, October 2021, Page 3375-3379 PDF (371.3 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2021.197729 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ahmed Mohamed Mansour Abd El Shafi  ; Abd El Wehab Fathi Ali; Mohammed Fakhery Mohamed Morsey
| ||||
| Abstract | ||||
| Background: Management of chronic infection with hepatitis C virus (HCV) with direct acting antivirals (DAAs) agents achieves high virological response. Recently, there is a matter of controversy about occurrence of hepatocellular carcinoma (HCC) following those agents. Objective: This study aimed to evaluate the efficacy of alpha fetoprotein (AFP) in development of HCC following DAAs therapy. Patients and methods: two hundred patients with chronic HCV infection who were eligible for DAAs therapy were recruited. Those patients were followed up for one year following therapy to detect development of HCC. Patients were grouped into either with normal AFP (100 patients) or high AFP (100 patients). Results: Majority (84%) of patients were males with overall mean age of 43.87±12.76 years. There were no significant differences between both groups of patients as regard baseline data. With exception of 4% of patients, all of them reached the sustained virological response (SVR). Frequency of HCC detection was higher among those patients with high AFP (9 (9%) vs 1 (1%); P< 0.001). We found that liver cirrhosis; FIB-4, APRI and AFP were predictors for HCC. AFP had the best diagnostic accuracy for prediction of HCC following DAAs Conclusion: Patients who received DAAs for HCV infection should be regularly screened for development of HCC. | ||||
| Keywords | ||||
| Hepatocellular carcinoma; Alpha fetoprotein; Direct acting antivirals | ||||
|
Statistics Article View: 160 PDF Download: 246 |
||||
